亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢楷倫公司銷售部  

埃索美拉唑,埃索美拉唑鎂三水合物,5-甲氧基-2-巰基-1H-苯并咪唑,頭孢雷特,普格拉雷等

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:童瑤
  • 電話:027-88395717
  • 郵件:kailun002@126.com
  • 傳真:027-88735683
  • QQ:2524490512
站內搜索
 
榮譽資質
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 168828-90-8利萘唑酮中間體的廠家
168828-90-8利萘唑酮中間體的廠家
單價 111.00 / kg對比
銷量 暫無
發貨 湖北武漢市付款后3天內
庫存 1kg起訂1kg
品牌 168828-90-8
型號 168828-90-8
規格 168828-90-8
過期 長期有效
更新 2013-09-26 11:11
 
詳細信息
(S)-N-3-(3'-氟-4'-嗎啉基)苯基-2-氧代-5-惡唑烷基甲基鄰苯二甲酰亞胺

168828-90-8利萘唑酮中間體的廠家中文名稱 (S)-N-3-(3'-氟-4'-嗎啉基)苯基-2-氧代-5-惡唑烷基甲基鄰苯二甲酰亞胺
英文名稱 (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine
中文別名 (S)-N-[[3-[3-氟-4-(4-嗎啉基)苯基]-2-氧代-5-惡唑烷基]甲基]胺;(S)-5-(氨基甲基)-3-(3-氟-4-嗎啉基苯基)-2-惡唑烷酮
CAS RN 168828-90-8
用  途 醫藥生物化工
利萘唑酮中間體
©2025 武漢楷倫公司銷售部 版權所有   技術支持:化工網   訪問量:10827  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |